Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + fruquintinib in dMMR/MSI-H colorectal cancer after ICI failure
ChiCTR2500111438Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and fruquintinib in colorectal cancer (CRC), sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500111438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111438.